Drugs / Sofosbuvir / Velpatasvir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06953479 | Jun 2025 → Jan 2027 expected | hepatitis C virus infection | Lifespan | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sofosbuvir / Velpatasvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06953479 ↗ |
| Known as | Epclusa | “Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]” NCT06953479 ↗ |
| Route | Oral | “Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]” NCT06953479 ↗ |